» Articles » PMID: 19276373

MicroRNA-205 Regulates HER3 in Human Breast Cancer

Overview
Journal Cancer Res
Specialty Oncology
Date 2009 Mar 12
PMID 19276373
Citations 173
Authors
Affiliations
Soon will be listed here.
Abstract

An increasing amount of experimental evidence shows that microRNAs can have a causal role in breast cancer tumorigenesis as a novel class of oncogenes or tumor suppressor genes, depending on the targets they regulate. HER2 overexpression is a hallmark of a particularly aggressive subset of breast tumors, and its activation is strictly dependent on the trans-interaction with other members of HER family; in particular, the activation of the PI3K/Akt survival pathway, so critically important in tumorigenesis, is predominantly driven through phosphorylation of the kinase-inactive member HER3. Here, we show that miR-205, down-modulated in breast tumors compared with normal breast tissue, directly targets HER3 receptor, and inhibits the activation of the downstream mediator Akt. The reintroduction of miR-205 in SKBr3 cells inhibits their clonogenic potential and increases the responsiveness to tyrosine-kinase inhibitors Gefitinib and Lapatinib, abrogating the HER3-mediated resistance and restoring a potent proapoptotic activity. Our data describe miR-205 as a new oncosuppressor gene in breast cancer, able to interfere with the proliferative pathway mediated by HER receptor family. Our study also provides experimental evidence suggesting that miR-205 can improve the responsiveness to specific anticancer therapies.

Citing Articles

Non-Coding RNAs in Breast Cancer: Diagnostic and Therapeutic Implications.

Benacka R, Szaboova D, Gulasova Z, Hertelyova Z Int J Mol Sci. 2025; 26(1.

PMID: 39795985 PMC: 11719911. DOI: 10.3390/ijms26010127.


miR-205 Regulates Tamoxifen Resistance by Targeting Estrogen Receptor Coactivator MED1 in Human Breast Cancer.

Ouyang B, Bi M, Jadhao M, Bick G, Zhang X Cancers (Basel). 2024; 16(23.

PMID: 39682180 PMC: 11640040. DOI: 10.3390/cancers16233992.


Edodes Cultured Extract Regulates Immune Stress During Puberty and Modulates MicroRNAs Involved in Mammary Gland Development and Breast Cancer Suppression.

Yasavoli-Sharahi H, Shahbazi R, Alsadi N, Robichaud S, Kambli D, Izadpanah A Cancer Med. 2024; 13(19):e70277.

PMID: 39382253 PMC: 11462599. DOI: 10.1002/cam4.70277.


HER3 receptor and its role in the therapeutic management of metastatic breast cancer.

Zhu M, Yu M, Meng Y, Yang J, Wang X, Li L J Transl Med. 2024; 22(1):665.

PMID: 39020378 PMC: 11253420. DOI: 10.1186/s12967-024-05445-8.


HER3-targeted therapy: the mechanism of drug resistance and the development of anticancer drugs.

Zeng H, Wang W, Zhang L, Lin Z Cancer Drug Resist. 2024; 7:14.

PMID: 38835349 PMC: 11149107. DOI: 10.20517/cdr.2024.11.